Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5127)
All Articles published online
|
Publishing Process of This Article
|
May 27, 2024 (publication date) through Jun 26, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Xie C, Alkhouri N, Elfeki MA. Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges. World J Hepatol 2024; 16(5): 731-750 [PMID: 38818288 DOI: 10.4254/wjh.v16.i5.731] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v16/i5/731.htm |
| Number | Citing Articles |
| 1 |
Yuansi Zheng, Jie Song, Qiuhui Qian, Huili Wang. Silver nanoparticles induce liver inflammation through ferroptosis in zebrafish. Chemosphere 2024; 362: 142673 doi: 10.1016/j.chemosphere.2024.142673
|
| 2 |
Ibrahim S. Alhomoud, Sarah E. Wheeler, Dave L. Dixon. Repurposing incretin therapies: a narrative review of emerging indications across cardiometabolic, liver, kidney, neurological, psychiatric, and other systems. Canadian Journal of Physiology and Pharmacology 2025; doi: 10.1139/cjpp-2025-0038
|
| 3 |
Queralt Martín‐Saladich, Rafael Simó, Andreea Ciudin, Julia Baguña, Clara Ramirez‐Serra, Santiago Aguadé‐Bruix, Albert Roque, Maria N. Pizzi, Hug Cuéllar, Nuria Roson‐Gradaille, Miguel A. González Ballester, Juan M. Pericàs, José Raul Herance. Phenotypic patterns of metabolic dysfunction‐associated steatotic liver disease in type 2 diabetes: The impact of insulin. European Journal of Clinical Investigation 2025; doi: 10.1111/eci.70050
|
| 4 |
Kathryn L. Williams, Maya Augustine, Eru Sujakhu, Justine Magadia, Lindsay Crawford, Aimee Knott, Skyler Hamilton, Uzoma Obiaka. Lipoprotein(a) in atherosclerotic cardiovascular disease, type 2 diabetes, and liver disease. Progress in Pediatric Cardiology 2025; 76: 101775 doi: 10.1016/j.ppedcard.2024.101775
|
| 5 |
Maryam Zafer, Federica Tavaglione, Manuel Romero‐Gómez, Rohit Loomba. Review Article: GLP‐1 Receptor Agonists and Glucagon/GIP/GLP‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD. Alimentary Pharmacology & Therapeutics 2025; 61(12): 1872 doi: 10.1111/apt.70196
|
| 6 |
Laura Pagès, Aina Martí-Carretero, Diego Rojo, Clara Sabiote, Farnaz Faninam, Sophia C. Parks, María Martínez-Gómez, M Serra Cusidó, Neda Akhlaghi, Sergio Muñoz-Martínez, Alba Jiménez-Masip, Juan M. Pericàs. GLP-1 and Glucagon Receptor Dual Agonists in the Management of Metabolic Dysfunction-associated Steatotic Disease (MASLD). Current Hepatology Reports 2025; 24(1) doi: 10.1007/s11901-025-00692-9
|
| 7 |
Francisco Capinha, Sofia Carvalhana, Helena Cortez-Pinto. Role of Alcohol in Steatotic Liver Disease: Impact on Patients with Cardiometabolic Risk Factors. Digestive Diseases and Sciences 2025; 70(5): 1746 doi: 10.1007/s10620-025-08912-4
|